MDA 19

MDA 19

• CAS Number: 1048973-47-2
• UNSPSC Description: MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity[1][2].
• Target Antigen: Cannabinoid Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/MDA-19.html
• Solubility: DMSO : 14.29 mg/mL (ultrasonic)
• Smiles: O=C(N/N=C1C(N(CCCCCC)C2=C\1C=CC=C2)=O)C3=CC=CC=C3
• Molecular Weight: 349.43
• References & Citations: [1]Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry (2008), 51(16), 4932-4947.|[2]Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported